(ASTE) for the treatment of patients with Duchenne muscular dystrophy (DMD) with AGAMREE under a Named Patient Program. The agreement enables ASTE, a pioneering healthcare distributor with over four ...
Abstract Highlights New Preclinical Data on Exosome-Based Delivery of PMOs for the Treatment of DMD-SAN DIEGO, Nov. 12, 2024 ...
Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on PepGen Inc. (PEPG – Research Report), with a price target of ...
Stockhead on MSN2h
Five ASX healthcare companies poised for game-changing catalystsEBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...
17mon MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...
Sarepta has stopped developing SRP-5051, its exon 51-skipping therapy for Duchenne MD, due to long-term safety concerns and ...
Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...
The candidate is intended to treat Duchenne muscular dystrophy (DMD). In October 2024, Capricor announced positive 3-year ...
Health company consulted with those living with disabilities for its messaging, along with hiring them as actors, producers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback